Sosei and InveniAI in drug discovery collaboration

InveniAI andi Sosei Group have announced a new R&D collaboration.

The collaboration will combine InveniAI’s AI-powered platform, AlphaMeld®, for target discovery with Sosei Heptares’ G-protein coupled receptor structure-based drug design and early development capabilities to generate and advance transformative therapeutics across disease indications that remain with high unmet medical needs.